C.D.C. Complete tandzorg has sold a stake to G Square Healthcare Pte. Equity
June 2015 — G Square Healthcare Private Equity (G Square) has invested in C.D.C. Complete tandzorg (CDC). The partnership will enable CDC to expand its complex dental care service offering to other regions in the Netherlands by opening new practices. Financial details have not been made public.
CDC has become Netherlands’ leading dental care provider for patients who need complex treatments. CDC is specialized in the construction, placement and maintenance of dental prosthesis such as bridges and crowns, dentures, click dentures and dental implants. In addition, CDC assists patients in finding the optimal dental care solution within their insurance coverage and budget and has a special dental program for children.
G Square is a London-based, independent private equity firm, targeting mid-sized healthcare companies in Europe. G Square Capital I is the first private equity fund managed by G Square and CDC is the sixth investment.
Dr. Laurent Ganem, President and founder of G Square, said: “We are delighted to invest in CDC and look forward to working together with its highly knowledgeable and experienced management. The anesthetic center and patient-oriented approach made CDC become a thriving dental care provider with a unique market position. We are very impressed with what has been achieved so far and believe that management has the capability to successfully replicate the model to other locations in the Netherlands.”
Eric and Rob Dral, founders and managers of CDC, said: “The pan-European healthcare and especially dental care experience of G Square is very attractive for us. We believe G Square is the perfect partner and will be able to support us in our growth objectives. Holland Corporate Finance and the UK-based Cavendish Corporate Finance, played a fundamental role in identifying G Square as a buyer and realizing the transaction in a dedicated and professional manner."
Our role in the transaction
Oaklins' team in the Netherlands, together with Oaklins Cavendish, based in the UK, advised the shareholders of CDC in this transaction. This deal is another example of the seamless cooperation between Oaklins' teams, demonstrating the organization’s added value through its global execution capabilities, industry expertise and contacts.
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreCibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more